Targeted Optical Imaging and Photodynamic Therapy
This review of photodiagnosis and phototherapy is a summary of specific aspects of optical targeting. It is not meant to be a comprehensive review, rather it is expected to serve both as an introduction of the approach for an audience outside the field of optical technologies. As such it is somewhat subjective and it is important for the reader to be aware that this is a very brief summary of literature and concepts in a rapidly emerging field. With the advent of new molecular probes and light delivery and light capturing techniques, it is likely that the field of optical treatment and diagnosis will have developed to such an extent in the next 5 years so as to make this writing irrelevant!
Many of the PS described throughout this chapter are potentially useful for both diagnosis and therapy. The fluorescence produced by these compounds may be exploited for several purposes: the identification and delineation of malignant tissues, the quantification of PS at the tumor site, and potentially the monitoring of oxygen and PS consumption during therapeutic light exposure. In an optimal scenario, targeted delivery identifies diseased tissue and in the same procedure treatment is delivered. A targeting molecule (MAb or peptide based) would deliver an optically activable agent specifically to tumors. This OAA would be used for diagnosis and treatment. The progressive improvement of remote imaging devices and molecular targeting strategies make this an attractive aim of preclinical and clinical development.
KeywordsPhotodynamic Therapy Fluence Rate Cheek Pouch PpIX Fluorescence Light Dosimetry
Unable to display preview. Download preview PDF.
- Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL (2003) Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J MedChem 46:3403–3411Google Scholar
- Chowdhary RK, Shariff I, Dolphin D (2003) Drug release characteristics of lipid based benzoporphyrin derivative. J Pharm Sci 6:13–19Google Scholar
- Hamblin MR, Tawakol A, Castano PA, Gad F, Zahra T, Ahmad A, Stern J, Ortel B, Chirico S, Shirazi A, Syed S, Muller JE (2003) Macrophage-targeted photodynamic detection of vulnerable atherosclerotic plaque. Proc SPIE (in press)Google Scholar
- Hasan T, Ortel B, Moor A, Pogue B (2003) Photodynamic therapy of cancer. In: Kufe DW, Pollack RE, Weichselbaum RR, et al. (eds) Cancer Medicine, 6th edn. B.C. Decker Hamilton, Ontario, pp 605–622Google Scholar
- Pogue BW, Hasan T (2003) Targeting in photodynamic therapy and photo-imaging. OPN 14:36–43Google Scholar
- Shin DM, Gimenez IB, Lee JS, Nishioka K, Wargovich MJ, Thacher S, Lotan R, Slaga TJ, Hong WK (1990) Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Cancer Res 50:2505–2510PubMedGoogle Scholar
- Vrouenraets MB, Visser GW, Loup C, Meunier B, Stigter M, Oppelaar H, Stewart FA, Snow GB, van Dongen GA (2000) Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. Int J Cancer 88:108–114PubMedCrossRefGoogle Scholar